Splenic lymphoma is a group of blood cancers that arise in or prominently involve the spleen, most commonly a slow-growing type called splenic marginal zone lymphoma (SMZL). Because the spleen is tucked behind the left ribcage and symptoms develop gradually, many people are diagnosed only after routine blood work turns up an abnormality or a doctor notices an enlarged spleen during an exam. The disease spans a wide clinical spectrum, from indolent forms that can be safely watched for years to aggressive variants that demand prompt treatment.
What Makes Splenic Lymphoma Different From Other Lymphomas
Most lymphomas are discovered when a swollen lymph node appears in the neck, armpit, or groin. Splenic lymphoma bucks that pattern. The disease is centered in the spleen and often in the bone marrow and blood, while peripheral lymph nodes stay normal-sized or only mildly enlarged. This unusual distribution is one reason it can be tricky to recognize. The most common form, SMZL, is classified as a low-grade B-cell lymphoma, meaning it grows slowly and involves a type of white blood cell called a B lymphocyte. A related presentation sometimes called “splenic lymphoma with villous lymphocytes” describes the same disease when abnormal B cells with hair-like projections circulate in the bloodstream.1PubMed. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients
True primary splenic lymphoma, where the cancer is confined entirely to the spleen, is rare. Far more often the spleen is involved as part of a lymphoma that has already spread.2PubMed Central. Primary Splenic Diffuse Large B-Cell Lymphoma: A Case Report But the term “splenic lymphoma” in everyday clinical use usually refers to any lymphoma whose dominant feature is spleen-centered disease, and SMZL is by far the most frequent example. The overall landscape ranges from the indolent SMZL to rare, aggressive entities like hepatosplenic T-cell lymphoma and primary splenic diffuse large B-cell lymphoma.3PubMed. Splenic lymphoma, diagnosis and treatment
Symptoms and How the Disease Shows Up
The hallmark finding is an enlarged spleen, called splenomegaly. You might feel a dull fullness or heaviness under your left ribs, early satiety (feeling stuffed after eating only a small amount), or occasional sharp left-sided pain. Some people notice nothing at all until a doctor palpates or images the spleen for an unrelated reason. Because the spleen filters blood cells, an oversized, lymphoma-infiltrated spleen can trap and destroy more cells than normal, leading to low blood counts. In one series of SMZL patients, about a third had elevated white-cell counts while roughly one in seven had abnormally low counts.4PubMed. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients
Fatigue is common and often dismissed as aging or stress. Some patients develop what oncologists call “B symptoms,” the triad of unexplained fevers, drenching night sweats, and unintentional weight loss. These systemic symptoms tend to signal more active disease and sometimes push the decision toward earlier treatment.
A less obvious but clinically important pattern involves autoimmune complications. Roughly a quarter of SMZL patients develop some form of autoimmune disorder, most often autoimmune destruction of red blood cells or platelets. In some cases these autoimmune problems are the very first sign of the lymphoma, appearing before anyone suspects cancer.5PubMed Central. Recurrent autoimmune hemolytic anemia in splenic marginal zone lymphoma Cold agglutinin disease, where antibodies attack red blood cells at cool temperatures, and cryoglobulinemia, where abnormal proteins thicken the blood in cold conditions, are among the immune-related presentations that can point toward splenic lymphoma.3PubMed. Splenic lymphoma, diagnosis and treatment
The Hepatitis C Connection
One of the more striking discoveries in this field is the link between hepatitis C virus (HCV) infection and SMZL. Studies have found HCV in roughly 10 to 16 percent of SMZL patients, a rate far higher than in the general population.6Hematology/Oncology and Stem Cell Therapy. Splenic marginal zone lymphoma associated with hepatitis B virus infection, remission after viral treatment, and splenectomy: A case report and review of the literature The prevailing theory is that chronic HCV infection drives ongoing stimulation of B cells in the spleen’s marginal zone, and over time that relentless activation tips some cells toward becoming cancerous.7PubMed. Hepatitis C virus infection and locally advanced splenic marginal zone lymphoma
The most compelling evidence for a direct role comes from treatment studies. In a landmark report, nine HCV-positive patients with splenic lymphoma with villous lymphocytes received antiviral therapy. Seven achieved complete remission once the virus became undetectable in their blood. The remaining two responded after adding a second antiviral drug. When one patient’s virus came back, so did the lymphoma. Meanwhile, none of the six HCV-negative patients responded to the same antiviral treatment.8PubMed. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection That pattern strongly suggests the virus itself is sustaining the cancer in these patients.
More recently, modern direct-acting antiviral drugs (the ones that now cure hepatitis C in weeks rather than months) have been tested as frontline therapy for HCV-associated indolent lymphomas. In a prospective study of 40 patients including 27 with marginal zone lymphoma, the lymphoma responded in about 45 percent of cases, with a fifth achieving complete remission.9PubMed Central. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi For HCV-positive patients with indolent splenic lymphoma, clearing the virus is now considered a reasonable first step before turning to chemotherapy or other lymphoma-directed treatments.
How Splenic Lymphoma Is Diagnosed
Diagnosing splenic lymphoma usually involves layering several kinds of evidence: blood tests, imaging, bone marrow examination, and sometimes a direct biopsy of the spleen itself.
Blood work often reveals circulating abnormal lymphocytes. In SMZL, these cells frequently have a characteristic “villous” appearance under the microscope, with tiny surface projections. Flow cytometry, a lab technique that identifies proteins on the surface of cells, helps distinguish SMZL from look-alike diseases such as hairy cell leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma. Getting this distinction right matters because the treatments differ substantially.
Bone marrow biopsy is a standard part of the workup. In one series, every single patient with SMZL showed marrow involvement, with the lymphoma cells characteristically nestled inside the marrow’s blood-carrying channels (an “intrasinusoidal” pattern).4PubMed. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients That infiltration pattern can be a helpful diagnostic clue even when the degree of involvement is subtle.
Imaging the Spleen
CT scans are the usual starting point for evaluating spleen size and looking for masses. But PET-CT, which highlights areas of high metabolic activity, adds another dimension. PET-CT is particularly valuable because it can detect lymphoma in a normal-sized spleen and in small lymph nodes that a CT scan might call unremarkable.10PubMed Central. Imaging Findings of Primary Splenic Lymphoma: A Review of 17 Cases in Which Diagnosis Was Made at Splenectomy When the two modalities were compared head-to-head for splenic staging in lymphoma patients, PET-CT together achieved perfect sensitivity, catching every case of splenic involvement.11PubMed. CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma That said, low-grade lymphomas like SMZL sometimes show only modest metabolic activity on PET, so a negative PET scan does not completely rule out involvement.
Splenic Biopsy
In the past, removing the spleen entirely (splenectomy) was often the only way to get a definitive tissue diagnosis. That is changing. Image-guided needle biopsy of the spleen, using CT or ultrasound to steer a thin needle into a suspicious area, is now considered safe and can reliably identify the lymphoma subtype in most patients.12PubMed. Imaging-guided percutaneous splenic biopsy using a 20- or 22-gauge cutting-edge core biopsy needle for the diagnosis of malignant lymphoma One series using ultrasound guidance achieved a diagnostic accuracy of about 77 percent, with only one case of minor bleeding that resolved without intervention.13Ultrasound in Medicine and Biology. Ultrasound-Guided Percutaneous Core Needle Biopsy of Splenic Lesions For patients who are poor surgical candidates or those for whom a tissue answer would change management, percutaneous biopsy offers a real alternative to going straight to the operating room.
Treatment Options
Treatment for splenic lymphoma, especially SMZL, is not one-size-fits-all. It ranges from doing nothing at all to surgery to drug therapy, depending on how aggressive the disease is and how much trouble it is causing.
Watch and Wait
Because SMZL is often indolent, many patients do not need treatment right away. A watch-and-wait approach, with regular blood tests and periodic imaging, is standard for people without significant symptoms and without severely low blood counts. In a large cohort of 62 asymptomatic, low-burden SMZL patients managed this way, the median time before treatment was needed stretched to nearly five years, and about one in six patients were still comfortably on watch-and-wait a full decade later.14PubMed. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era The idea can be unsettling, living with a known cancer and not treating it. But for truly low-risk patients, holding off avoids the side effects of treatment without sacrificing long-term outcomes.
Rituximab
When treatment is needed, rituximab, an antibody drug that targets the CD20 protein on B cells, has become the preferred first option for most SMZL patients. Response rates are high: across published series, more than 90 percent of patients respond, and about half achieve complete remission.15Best Practice & Research Clinical Haematology. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma? In one prospective study, the overall response rate was 95 percent, and patients who went on to receive maintenance rituximab (periodic re-dosing after the initial course) had a five-year progression-free survival of 84 percent, compared with 36 percent for those who did not receive maintenance.16PubMed Central. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy That maintenance benefit is large and has helped solidify rituximab’s position as the first-line treatment of choice.
Splenectomy
Removing the spleen was historically the go-to treatment. It rapidly relieves the physical burden of a massively enlarged organ, and blood counts typically improve quickly afterward. The median time before the lymphoma progresses after splenectomy is about five years.17PubMed. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? But SMZL is a systemic disease, already in the bone marrow and blood in most patients, so splenectomy is not done with the intent to cure. It carries real surgical risks, especially in older adults, and it permanently removes an organ that plays a role in fighting certain infections. A population-level analysis found no significant survival advantage for patients who had their spleens removed compared with those who did not.18PubMed. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma
Splenectomy still has a role, particularly when the spleen is so large it is causing severe symptoms or dangerously low blood counts that have not responded to rituximab, or when tissue is needed for diagnosis. When it is performed, laparoscopic (keyhole) surgery is preferred over open surgery for its faster recovery and lower complication rates.19PubMed Central. Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma But the overall trend in the field has been to reserve surgery for situations where other options fall short.
Chemotherapy and Newer Agents
Combination chemotherapy, often rituximab plus one or more chemotherapy drugs, tends to be reserved for patients with more aggressive presentations, transformation to a higher-grade lymphoma, or disease that has relapsed after initial treatment. For patients whose SMZL comes back after rituximab, or who have the rarer aggressive splenic lymphoma subtypes, options are expanding. The BTK inhibitor zanubrutinib was recently approved for relapsed or refractory marginal zone lymphoma, offering a targeted oral therapy that works by blocking a signaling molecule that lymphoma cells depend on for survival.20PubMed. Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches
Prognosis and Risk Stratification
For most people with SMZL, the outlook is favorable. A validated prognostic model divides patients into three risk groups based on a small number of clinical variables. About 40 percent of patients fall into a low-risk category, where the five-year disease-specific survival rate is roughly 88 percent. About a third land in an intermediate category, with a five-year survival of around 73 percent. The remaining quarter are high-risk, with five-year survival near 50 percent. That high-risk group accounts for more than half of all lymphoma-related deaths.21PubMed. Splenic marginal zone lymphoma: a prognostic model for clinical use The key factors that push someone into a higher risk category include markers of disease burden and aggressive biology, such as anemia, elevated lactate dehydrogenase, and low albumin levels.
Genetic studies have identified recurring mutations in genes like KLF2, NOTCH2, and TP53, as well as chromosomal abnormalities such as loss of part of chromosome 7.22Exploration of Targeted Anti-tumor Therapy. The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications TP53 mutations in particular are associated with a more aggressive course. As molecular testing becomes more routine, these genetic markers are likely to play a growing role in deciding who can be safely watched and who needs early, more intensive treatment.
Transformation to Aggressive Lymphoma
The most feared complication of SMZL is transformation into diffuse large B-cell lymphoma (DLBCL), a fast-growing cancer that requires prompt chemotherapy. Transformation is uncommon but not negligible. Among the marginal zone lymphoma subtypes, splenic MZL carries the highest transformation risk, with a cumulative incidence of about 5 percent, compared with lower rates for the nodal and extranodal forms.23Cancer Epidemiology. Splenic Lymphoma Linked to High Risk of DLBCL Transformation When transformation occurs, it can involve the bone marrow, lymph nodes, or even the brain.24PubMed Central. High-Grade Transformation in a Splenic Marginal Zone Lymphoma with a Cerebral Manifestation Survival drops significantly after transformation regardless of the original MZL subtype, which is why clinicians keep a close eye on patients even during watch-and-wait periods. A sudden spike in symptoms, rapidly falling blood counts, or a new area lighting up on PET should raise the question of transformation.
Living Without a Spleen
If you do end up having a splenectomy, the long-term implications go beyond the lymphoma itself. The spleen helps the body fight encapsulated bacteria, the kinds that cause pneumonia, meningitis, and certain bloodstream infections. Without it, you are at lifelong elevated risk for overwhelming post-splenectomy infection, a rare but potentially fatal condition. Vaccination against pneumococcus, meningococcus, and Haemophilus influenzae type b is essential before or soon after surgery, along with an annual flu shot. Some doctors also prescribe a standing supply of antibiotics for patients to keep on hand and start immediately if they develop a high fever, buying time to get medical attention. Wearing a medical alert bracelet is a common recommendation so that emergency providers know about the absent spleen. These precautions are straightforward but genuinely important, and they are lifelong rather than temporary.
When Splenomegaly Is Not Lymphoma
An enlarged spleen has a long list of possible causes, and lymphoma is only one of them. Infections (including mononucleosis, malaria, and viral hepatitis), liver disease with portal hypertension, autoimmune conditions like lupus, and other blood disorders such as myelofibrosis can all produce a big spleen. Doctors work through these possibilities before settling on a lymphoma diagnosis. One practical point for patients: an incidentally discovered enlarged spleen on an abdominal scan is more often explained by something other than cancer. The diagnostic workup described above, combining blood tests, flow cytometry, marrow biopsy, and imaging, exists precisely to sort lymphoma from these many other causes so that treatment is appropriately targeted rather than reflexive.